Diaceutics (DXRX) Share Price, News & Analysis

Company Overview

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

Key Stats

• Today's Range: 149 to 152
• 50-Day Range: 119 to 150
• 52-Week Range: 106 to 152
• Volume: 129,323 shs
• Average Volume: 150,293 shs
• Market Capitalization: £126.82 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: GBX 175
• Consensus Rating: Buy

Diaceutics Stock Analysis - MarketRank™

Diaceutics scored higher than 21% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Buy

Consensus Rating

Diaceutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Diaceutics has a consensus price target of GBX 175, representing about 16.3% upside from its current price of GBX 150.50.

Amount of Analyst Coverage

Diaceutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Diaceutics is -7,450.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Diaceutics is -7,450.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Diaceutics has a P/B Ratio of 3.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for DXRX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Diaceutics does not currently pay a dividend.

Dividend Growth

Diaceutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for DXRX.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Diaceutics this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for DXRX on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Diaceutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

26.34% of the stock of Diaceutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 24.74% of the stock of Diaceutics is held by institutions.

DXRX Stock Analysis - Frequently Asked Questions

How have DXRX shares performed this year?

Diaceutics' stock was trading at GBX 123 on January 1st, 2025. Since then, DXRX stock has increased by 22.4% and is now trading at GBX 150.50.

How were Diaceutics' earnings last quarter?

Diaceutics PLC (LON:DXRX) released its earnings results on Tuesday, May, 13th. The company reported ($2.02) earnings per share (EPS) for the quarter. Diaceutics had a negative net margin of 10.90% and a negative trailing twelve-month return on equity of 7.15%.

How do I buy shares of Diaceutics?

Shares of DXRX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Diaceutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Diaceutics investors own include 4D pharma (DDDD), Rolls-Royce Holdings plc (RR.L), Abcam (ABC), B&M European Value Retail (BME), BP (BP), Coats Group (COA) and genedrive (GDR).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 9/22/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: N/A
• Current Symbol: LON:DXRX
• CIK: N/A
• Web: www.diaceutics.com
• Phone: N/A
• Fax: N/A
• Employees: 151
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Diaceutics: GBX 175
• High Price Target: GBX 185
• Low Price Target: GBX 160
• Potential Upside/Downside: +16.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): GBX (0.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 148.40
• P/E Growth: N/A
• Net Income: -£2.84 million
• Net Margins: -10.90%
• Pretax Margin: N/A
• Return on Equity: -7.15%
• Return on Assets: -6.06%

Debt

• Debt-to-Equity Ratio: 0.39
• Current Ratio: 4.85
• Quick Ratio: 9.92

Sales & Book Value

• Annual Sales: £32.16 million
• Price / Sales: 3.94
• Cash Flow: GBX 48.08 per share
• Price / Cash Flow: 3.12
• Book Value: GBX 45.87 per share
• Price / Book: 3.27

Miscellaneous

• Outstanding Shares: 84,547,000
• Free Float: N/A
• Market Cap: £126.82 million
• Optionable: Not Optionable
• Beta: 0.58